Everest to receive ~$455M incl. $280M up front and ~$175M upon achievement of regulatory & commercial milestones. The transaction is expected to close in 2022
Gilead to get exclusive rights to develop & commercialize Trodelvy in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia & Mongolia. The collaboration helps to expand the product portfolio & internal drug discovery efforts for Trodelvy
Under the 2019 agreement with Immunomedics, Everest got an exclusive license for Trodelvy in Greater China & other countries (Ex–Japan). Trodelvy was approved in China mainland & Singapore for m-TNBC. Everest has submitted the NDA of Trodelvy for m-TNBC with regulatory bodies in South Korea, Taiwan & Hong Kong
Ref: Gilead | Image: Gilead
